<DOC>
	<DOC>NCT00593554</DOC>
	<brief_summary>The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality (TRM) rate at 6 months.</brief_summary>
	<brief_title>Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Patients must have histologically documented AML, ALL, MDS, CML, Acute myeloid leukemia (AML) with one or more of the following criteria CR 1 with poor risk features CR 2, or higher order CR Acute lymphoblastic leukemia (ALL) with one of the following criteria CR 1 with poor risk features CR 2, or higher order CR Myelodysplasia, RAEB I Donor has been identified Age â‰¤ 65 years. Performance Status 01. Patients relapsing &lt;6 months after autologous SCT are not eligible. Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection. Nonpregnant and nonnursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>